独家专访百利天恒创始人朱义：一个全球首创新药撑起我们2000亿市值将“绰绰有余”｜上海药圈新拐点

Core Viewpoint - Bailitianheng has gained significant attention in the capital market due to a 13-fold increase in stock price over two years, its status as the richest company on the Sci-Tech Innovation Board, and its innovative cancer drug, which is considered a breakthrough in the Chinese biopharmaceutical industry [1] Company Insights - The founder of Bailitianheng, Zhu Yi, has addressed both praise and skepticism from the public regarding the company's rapid growth and innovation [1] - The company aims to evolve into a multinational pharmaceutical enterprise originating from China, indicating its ambition for global expansion [1] Industry Context - The developments surrounding Bailitianheng are viewed as a gamble on innovative pharmaceuticals, reflecting broader trends and challenges within the Chinese biopharmaceutical sector [1] - The company is planning to establish a new strategic presence in Shanghai, which signifies its intent to further its market reach and operational capabilities [1]